RBF Symposium

February 4, 2013 Pre-symposium workshop
08.00 hrs onwards	Registration and Morning Coffee
08.45 hrs	Chairpersons Opening Remarks
09.00 – 10.00 hrs	Potential of Cellular analysis in Drug Discovery and Early Toxicology studies– The GE Healthcare Integrated Platform GE Healthcare
10.00 – 11.00 hrs	Semiconductor sequencing- a boon to translational Research Life Technologies
11.00 – 11.30 hrs	Tea Break
11.30 – 12.30 hrs	Paper Trails to Electronic Data Management PerkinElmer (Informatics)
12.30 – 13.30 hrs	High Resolution Mass Spectrometry for Pharmaceutical Applications AB SciEx
13.30 – 15.00 hrs	Lunch, Poster & Networking session
15.00 – 16.00 hrs	Innovative strategy to locate, screen and identify new chemical entities using STN and SciFinder databases Sci-Edge Information
16.00 – 17.00 hrs	Drug transporters in drug discovery: methods and regulatory considerations Solvo Biotechnology, Hungary
17.00 – 18.30 hrs	Application of High Resolution Mass Spectrometry and Ion Mobility Separations for Systems Biology Applications Introducing the latest Waters MS technology platforms Protein profiling and biomarker validation Protein characterization Metabonomics and structural elucidation Lipidomics and lipid characterization Imaging by Mass Spectrometry Waters Ltd.

February 5, 2013
08.30 – 09.00 hrs		Morning Coffee
09.00 – 09.30 hrs		Inauguration
09.30 – 10.30 hrs		Keynote Address A Chemist’s Foray into Translational Research Dr. Peter Schultz Director, Calibr Institute, Professor of Chemistry, The Scripps Research Institute, USA Founder of Affymax Research Institute, Syrrx, Kalypsys, Phenomix, Symyx Therapeutics, Ilypsa, Ambrx, Ardelyx, and Wildcat Technologies
10.30 – 11.00 hrs		Tea Break
11.00 – 11.45 hrs		Keynote Address Peptide Therapeutics and the Quest For Differentiated Medicines Dr. Pierre Rivière Sr. Vice President, Global R&D, Pfizer, USA
11.45 – 12.30 hrs		Frontloading Toxicity Detection in order to Lower Costs and Attrition Dr. Bruce Car Vice President, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, USA
12.30 – 13.15 hrs		Western biotech & Emerging Market pharma alliances: explosive value creation or hype? Dr. Stephen Yoder CEO, Pieris AG, Germany
13.15 – 15.00 hrs		Lunch, Poster & Networking session
15.00 – 15.45 hrs		Playing the numbers game in small-molecule lead discovery Dr. Alex Haahr Gouliaev CEO, Nuevolution, Denmark
15.45 – 16.30 hrs		“Studies Towards Development Of Pcsk9 Inhibitors For Regulating LDL-R and Cholesterol” Dr. Ajoy Basak Department of Biochemistry, Microbiology & Immunology, Faculty of Medicine and Interdisciplinary School of Health Sciences, University of Ottawa, Canada
16.30 – 17.00 hrs		Tea Break
17.00 – 17.45 hrs		FGF21-Adnectin-Pharmacokinetic Enhancer: A modified FGF21 protein with uniquely extended Pharmacokinetic Profile for the Treatment of Metabolic Diseases. Dr. Ranjan Mukherjee Department of Metabolic Diseases, Bristol-Myers Squibb Company, USA
17.45 – 18.30 hrs		Inflammation, Mitochondrial Dysfunction and Insulin Resistance- implications for antidiabetic drug discovery. Dr. Satinath Mukhopadhyay Professor, Department of Endocrinology and Metabolism, Institute of Postgraduate Medical Education & Research, Kolkata, india.
18.30 – 19.15 hrs	*Panel discussion*	Dr. Peter Schultz Dr. Pierre Rivière Dr. Bruce Car Dr. Alex Haahr Gouliaev Dr. Stephen Yoder Dr. Ranjan Mukherjee Dr. Satinath Mukhopadhyay Dr. Ajoy Basak Dr. Kapil Dhingra

February 6, 2013
08.00 – 08.30 hrs		Morning Coffee
08.30 – 09.15 hrs		Keynote Address Oncology 2013: Recent advances in personalized therapy of cancer Dr. Kapil Dhingra Retired Vice President, Head, Oncology Disease Biology Leadership Team, Roche, Director, KAPital Consulting LLC, USA
09.15 – 10.00 hrs		Keynote Address Combined Targeted Therapy in Sarcomas-Pathways to Success? Dr. Lee Helman Head & Senior Investigator, Molecular Oncology Section, National Cancer Institute, USA
10.00 – 10.30 hrs		Tea Break
10.30 – 11.15 hrs		Personalized Therapy in Oncology - what they don’t tell you Dr. Purvish M. Parikh Managing Director, AmeriCares, India
11.15 – 12.00 hrs		Novalties on BCR/ABL Dr Martin Ruthardt Head, Laboratory of Tumor Stem Cell Biology, Univeristy of Frankfurt, Germany
12.00 – 12.45 hrs		Disease, Process and Partners: Challenges of Biomarker and Diagnostic Development in Oncology Dr Anjan Thakurta Sr. Director, Translational Development, Celgene, USA
12.45 – 13.30 hrs		Lunch, Poster & Networking session
13.30 – 14.00 hrs		Locks, Clocks and Peacocks Dr. Hiren Shah Ahmedabad, India
14.00 – 14.45 hrs		Keynote Address Adjuvants to Enable Next Generation Vaccines Dr. Steven G. Reed Founder, President, & Chief Scientific Officer, Infectious Disease Research Institute, USA
14.45 – 15.30 hrs		TLR7 in oncology and as an adjuvant Dr. Johanna Holldack Chief Executive Officer, Telormedix SA, Switzerland
15.30 – 16.00 hrs		Tea Break
16.00 – 16.45 hrs		Predicting responses to vaccination with systems biology: What have we learned so far ? Dr. Jan ter Meulen Executive Director, Vaccine Research, Merck Research Laboratories, USA
16.45 – 17.30 hrs	Panel Discussion	Dr. Kapil Dhingra Dr. Lee Helman Dr. Purvish M. Parikh Dr Anjan Thakurta Dr. Johanna Holldack Dr. Steven G. Reed Dr. Jan ter Meulen
17.30 – 18.00 hrs		Best Poster Award Lecture 1 & 2
18.00 hrs		Vote of Thanks